Anna Greka joins Ovid Therapeutics (NASDAQ: OVID) board, expanding it to seven
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Ovid Therapeutics Inc. appointed Anna Greka, M.D., Ph.D. to its Board of Directors as a Class III director, effective June 15, 2026. Her term will run until the company’s 2029 annual meeting of stockholders, at which point she would be eligible for re-election.
With her appointment, the Board will expand to seven directors. Dr. Greka will serve on the Compensation Committee and the Science and Technology Committee. She is a Professor of Medicine at Harvard Medical School and holds multiple leadership roles at the Broad Institute, bringing deep scientific and biotech advisory experience.
As a non-employee director, Dr. Greka will receive compensation under Ovid’s standard non-employee director compensation policy and has entered into the company’s standard indemnification agreement. The company states there are no related-party relationships or arrangements requiring disclosure under Regulation S-K Item 404(a).
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Effective appointment date: June 15, 2026
Board size after change: 7 directors
Director term end: 2029 annual meeting
+1 more
4 metrics
Effective appointment date
June 15, 2026
Date Anna Greka joins the Board
Board size after change
7 directors
Board size effective June 15, 2026
Director term end
2029 annual meeting
End of Class III director term
Director age
50 years
Age of Anna Greka at appointment
Key Terms
Class III director, Nominating and Corporate Governance Committee, non-employee director compensation policy, indemnification agreement, +1 more
5 terms
Class III director regulatory
"appointment of Anna Greka, M.D., Ph.D., as a Class III director of the Company"
A Class III director is a board member placed in one of the numbered groups used by companies with a staggered (or “classified”) board; that director’s seat typically comes up for election in the third year of a three-year rotation. For investors this matters because staggered terms create continuity but also make it harder to replace the whole board quickly, affecting shareholder influence, takeover dynamics and how fast new strategy or accountability can be implemented — like replacing only some players on a sports team each season instead of the whole roster at once.
Nominating and Corporate Governance Committee regulatory
"upon recommendation of the Nominating and Corporate Governance Committee of the Board"
A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.
non-employee director compensation policy financial
"compensation for her board and committee service consistent with the Company’s non-employee director compensation policy"
indemnification agreement regulatory
"The Company and Dr. Greka also entered into the Company’s standard form of indemnification agreement."
An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.
Item 404(a) of Regulation S-K regulatory
"requiring disclosure under Item 404(a) of Regulation S-K."
FAQ
What did Ovid Therapeutics (OVID) announce in this 8-K filing?
Ovid Therapeutics announced the appointment of Anna Greka, M.D., Ph.D., as a Class III director effective June 15, 2026. Her term will run until the company’s 2029 annual meeting of stockholders, and the Board will increase to seven members.
Who is Anna Greka and what is her background relevant to OVID?
Anna Greka is a Professor of Medicine at Harvard Medical School and a leader at the Broad Institute. She has extensive experience founding, advising and working with biopharmaceutical companies, which aligns with Ovid Therapeutics’ focus on biotechnology and drug development.
What board committees will Anna Greka serve on at Ovid Therapeutics (OVID)?
Anna Greka will serve on Ovid Therapeutics’ Compensation Committee and its Science and Technology Committee. These roles place her directly in oversight of executive pay and the company’s scientific and technological direction, leveraging her academic and biotech experience.
When does Anna Greka’s term as Ovid Therapeutics (OVID) director end?
Anna Greka’s term as a Class III director will expire at Ovid Therapeutics’ 2029 annual meeting of stockholders. At that meeting, shareholders could vote on her re-election under the company’s standard director nomination and election process.
How will Anna Greka be compensated for her role at Ovid Therapeutics (OVID)?
Anna Greka will receive compensation consistent with Ovid Therapeutics’ non-employee director compensation policy. The company refers investors to its April 27, 2026 definitive proxy statement, which describes director compensation under the Executive Officer and Director Compensation—Director Compensation section.